Zobrazeno 1 - 10
of 60
pro vyhledávání: '"N. Guajardo-Jauregui"'
Autor:
N Guajardo-Jauregui, DA Galarza-Delgado, IJ Colunga-Pedraza, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/9300e513f16d42988c4132c527a274cf
Autor:
N Guajardo-Jauregui, DA Galarza-Delgado, IJ Colunga-Pedraza, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/0ef4142ec870494f87ae7876dd403462
Autor:
N Guajardo-Jauregui, DA Galarza-Delgado, IJ Colunga-Pedraza, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/b87c9ef0c4f3427fba83cb015d65b3a6
Autor:
N Guajardo-Jauregui, DA Galarza-Delgado, IJ Colunga-Pedraza, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/d8bc10a2d7c24087a4e8669ce3e6f79b
Autor:
N Guajardo-Jauregui, IJ Colunga-Pedraza, DA Galarza-Delgado, JR Azpiri-Lopez, JA Cardenas-De La Garza, S Lugo-Perez
Publikováno v:
Thursday 06 October 2022 from 13:00 to 14:10.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6d8a67bd190f4aad493fd996238aa6d
https://doi.org/10.1136/lupus-2022-elm2022.88
https://doi.org/10.1136/lupus-2022-elm2022.88
Autor:
Jesus Alberto Cardenas-de la Garza, Andrea Cecilia Garza-Acosta, José Ramón Azpiri-López, S. Lugo-Perez, N. Guajardo-Jauregui, R.I. Arvizu-Rivera, Gisela García-Arellano, Dionicio Ángel Galarza-Delgado, A. B. Rodriguez-Romero, Octavio Ilizaliturri-Guerra, Iris Jazmin Colunga-Pedraza, Diana Elsa Flores-Alvarado
Publikováno v:
Clinical rheumatology. 41(5)
The objective was to compare the prevalence of subclinical atherosclerosis and cardiovascular risk (CVR) reclassification using six CVR algorithms and a carotid ultrasound in psoriatic arthritis (PsA) patients and controls. The method was cross-secti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4371529029ead3e41faa0bd91b95857
https://pubmed.ncbi.nlm.nih.gov/34826020
https://pubmed.ncbi.nlm.nih.gov/34826020
Autor:
N. Guajardo-Jauregui, A. B. Rodriguez-Romero, Iris Jazmin Colunga-Pedraza, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Alberto Cardenas-de la Garza, Dionicio Ángel Galarza-Delgado, José Ramón Azpiri-López, S. Lugo-Perez, Andrea Cecilia Garza-Acosta
Publikováno v:
Annals of the rheumatic diseases. 80(12)
Psoriatic arthritis (PsA) is a chronic, inflammatory and immune-mediated disease that affects up to 30% of psoriasis (PsO) patients.1 Nail involvement affects 80% of PsA patients and 30%–50% of PsO patients. Nail PsO has been associated with worse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59e0dec5edaa70ab9a0289ff072aa329
https://pubmed.ncbi.nlm.nih.gov/34167948
https://pubmed.ncbi.nlm.nih.gov/34167948
Autor:
N. Guajardo-Jauregui, D. Á. Galarza-Delgado, J. R. Azpiri-López, I. J. Colunga-Pedraza, A. Cárdenas, A. N. Garza-Cisneros, A. Garcia-Heredia, M. A. Balderas-Palacios, A. B. Rodriguez-Romero
Publikováno v:
Annals of the Rheumatic Diseases. 81:1237.2-1238
BackgroundCardiovascular (CV) disease is the major cause of death of RA patients. There is a direct association of systemic inflammation and an accelerated process of atherosclerosis, which is related to higher CV morbimortality (1). Additionally, RA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d723de139aff34b9be5b9409210ca97
https://doi.org/10.1136/annrheumdis-2022-eular.4215
https://doi.org/10.1136/annrheumdis-2022-eular.4215
Autor:
N. Guajardo-Jauregui, J. R. Azpiri-López, I. J. Colunga-Pedraza, D. Á. Galarza-Delgado, A. Cárdenas, A. N. Garza-Cisneros, A. Garcia-Heredia, M. A. Balderas-Palacios, A. B. Rodriguez-Romero
Publikováno v:
Annals of the Rheumatic Diseases. 81:1398.2-1399
BackgroundSystemic lupus erythematosus (SLE) patients have a worse cardiovascular prognosis than the general population. It is estimated that approximately 40% of SLE patients develop lupus nephritis (LN) throughout the evolution of the disease (1).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35fe092ef5353781d1561c143746b7e9
https://doi.org/10.1136/annrheumdis-2022-eular.4220
https://doi.org/10.1136/annrheumdis-2022-eular.4220
Autor:
M. A. Balderas-Palacios, I. J. Colunga-Pedraza, D. Á. Galarza-Delgado, J. R. Azpiri-López, A. B. Rodriguez-Romero, A. N. Garza-Cisneros, A. Garcia-Heredia, N. Guajardo-Jauregui, A. Cárdenas
Publikováno v:
Annals of the Rheumatic Diseases. 81:1228.2-1228
BackgroundThe main cause of death in patients with rheumatoid arthritis (RA) is due to cardiovascular disease1. Cardiovascular mortality is strongly associated with the cumulative severity of the disease. Functional disability, as measured by the Hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3165f36c1bfad1fd8aeabb3285c19d0c
https://doi.org/10.1136/annrheumdis-2022-eular.3406
https://doi.org/10.1136/annrheumdis-2022-eular.3406